Please wait while the transcript is being prepared...
0:00
Hello everyone I'm very
happy to talk today about
"Clinical Imaging Features of
Cerebral Amyloid Angiopathy."
I'm Dr. Gregoire Boulouis, I am
Neuro-Radiology Attending to
a University hospital and I
wanted to give a
special thanks to
Dr. Andreas Charidimou
and officials
Pr JC Baron for the assistance
in preparing this talk today.
0:23
Today we'll be covering from
pathological substrate to
imaging biomarkers, then from
artifacts to imaging
biomarkers and then we'll see
how we can use CAA imaging
biomarkers in clinical practice.
We start with a
short introduction.
0:40
A short introduction as you know
cerebral amyloid angiopathy is
a disease of microvessels and
when you use clinical
imaging, like
clinical MRI, you only get a
millimetric resolution that's
a top resolution using 3T MRI is
half a millimeter
that's 500 microns.
And the microvessels
you're investigating are more in
the ten micron
range so you don't
get to see the microvessels.
So you need to be able to reason
clinically other markers than the
disease you're investigating.
And these markers need to be
visible, measurable and diverse.
You also need actionable
thresholds to make
your diagnosis or have
a prognostic reasoning.
And you also need to
have means to exclude
differential diagnosis.
And in the context of clinical
practice there is a need for
consensual scales/definition,
something that's reproducible
and that means a homogeneous
nosology in the sense that
everyone speaks
the same language
and that's what we're
going to try to see.
